300
Participants
Start Date
September 13, 2024
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
Orforglipron
Administered orally
Placebo
Administered orally
Weill Cornell Medical College, New York
PharmQuest Life Sciences, LLC, Greensboro
Tribe Clinical Research, LLC, Greenville
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City
New Horizon Research Center, Miami
Cahaba Research - Pelham, Pelham
Cahaba Research, Birmingham
WR-Clinsearch, LLC, Chattanooga
Prime Health and Wellness/SKYCRNG, Fayette
L-MARC Research Center, Louisville
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Iowa Diabetes and Endocrinology Research Center, West Des Moines
Lillestol Research, Fargo
StudyMetrix Research, City of Saint Peters
Alliance for Multispecialty Research, LLC, Norman
Southern Endocrinology Associates, Mesquite
Velocity Clinical Research, Dallas, Dallas
North Texas Endocrine Center, Dallas
Biopharma Informatic, LLC, Houston
PlanIt Research, PLLC, Houston
The University of Texas Health Science Center at Houston, Bellaire
Rocky Mountain Clinical Research, Idaho Falls
Palm Research Center Tenaya, Las Vegas
Palm Research Center Sunset, Las Vegas
Encompass Clinical Research, Spring Valley
Southern California Dermatology, Inc., Santa Ana
University Clinical Investigators, Inc., Tustin
Puerto Rico Medical Research, Ponce
Wellness clinical Research Vega Baja, Vega Baja
Eli Lilly and Company
INDUSTRY